Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Should You Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $15.5580, but opened at $14.45. Ono Pharmaceutical shares last traded at $14.45, with a volume of 459 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has an average rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The company has a market cap of $6.79 billion, a price-to-earnings ratio of 14.60 and a beta of 0.34. The company has a fifty day moving average of $14.42 and a two-hundred day moving average of $14.69.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.